Iryna Drozd
Sana Biotechnology (NASDAQ:SANA) said the FDA has cleared its Investigational New Drug application to initiate a clinical study of its drug candidate SC262 in the treatment of relapsed or refractory B-cell malignancies.
The product will be tested initially in patients who have already been treated with a CD 19-directed CAR T therapy.
